Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

Abstract Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti‐CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti‐CD20 antibodies can increase hypogammaglobulinemia risk, while the effects of Ven on immune dysregulation ar...

Full description

Bibliographic Details

Published in:	HemaSphere
Main Authors:	Arnon P. Kater, Barbara F. Eichhorst, Carolyn J. Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Online Access:	https://doi.org/10.1002/hem3.146